Impact of G-CSF prophylaxis on the occurrence of neutropenia in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel.

Authors:
  • SOS. Oudard
    S. Oudard
  • ASA. O. Sartor
    A. O. Sartor
  • SHS. Hansen
    S. Hansen
  • JMJ. H. Machiels
    J. H. Machiels
  • LSL. Shen
    L. Shen
  • JBJ. S. De Bono
    J. S. De Bono
  • FIFor the TROPIC investigators
    For the TROPIC investigators

Abstract
E15131^ Background: The Phase III TROPIC trial demonstrated that cabazitaxel plus prednisone (CbzP) improved overall survival compared with mitoxantrone plus prednisone (MP) in patients with mCRPC who progressed during or after docetaxel-based therapy (HR 0.70; p < 0.0001) (Lancet 2010; 376:1147–54). A higher proportion of men in the CbzP group had Grade ≥ 3 neutropenia (82% vs. 58%) and febrile neutropenia (FN) (8% vs. 1%) compared with MP. In patients clinically predisposed to neutropenia, ASCO guidelines recommend prophylaxis with granulocyte-colony stimulating factor (G-CSF) and/or dose reductions. We analyzed the effect of G-CSF use on neutropenia in TROPIC. Methods: Men with mCRPC (n=755) who progressed during or after docetaxel were randomized to receive CbzP (n=378) or MP (n=377). Primary prophylaxis with G-CSF for neutropenia was not allowed in cycle 1, but G-CSF use was permitted from cycle 2 onward following a first occurrence of neutropenia with protocol-defined complications. G-CSF use was cl...